CAS Medical Systems, Inc. (CASM) EPS Estimated At $-0.07

July 14, 2018 - By Elena Maslow

CAS Medical Systems, Inc. (NASDAQ:CASM) LogoInvestors sentiment increased to 1.4 in 2018 Q1. Its up 0.40, from 1 in 2017Q4. It improved, as 2 investors sold CAS Medical Systems, Inc. shares while 3 reduced holdings. 2 funds opened positions while 5 raised stakes. 6.50 million shares or 1.24% more from 6.42 million shares in 2017Q4 were reported.
California Public Employees Retirement Sys holds 0% in CAS Medical Systems, Inc. (NASDAQ:CASM) or 10,400 shares. 22,400 were reported by Penbrook Mgmt Ltd Liability. Ontario – Canada-based Royal Savings Bank Of Canada has invested 0% in CAS Medical Systems, Inc. (NASDAQ:CASM). Wells Fargo And Mn owns 227 shares. Bancshares Of America De owns 541 shares for 0% of their portfolio. Horizon Kinetics Llc reported 99,546 shares. Acuta Capital Prtnrs Limited Liability has invested 1.07% in CAS Medical Systems, Inc. (NASDAQ:CASM). Guggenheim Capital holds 0% in CAS Medical Systems, Inc. (NASDAQ:CASM) or 12,246 shares. Hightower Advsrs Lc holds 0% or 240,889 shares. Moreover, Rmb Cap Mgmt Ltd Liability Com has 0% invested in CAS Medical Systems, Inc. (NASDAQ:CASM). 532,365 were accumulated by Vanguard Group Inc Inc. Blackrock holds 12,566 shares or 0% of its portfolio. Morgan Stanley stated it has 2,378 shares. Renaissance Technologies Limited Liability has invested 0% of its portfolio in CAS Medical Systems, Inc. (NASDAQ:CASM). Northern Corporation accumulated 25,101 shares.

Since March 15, 2018, it had 0 buys, and 4 insider sales for $44,489 activity.

Analysts expect CAS Medical Systems, Inc. (NASDAQ:CASM) to report $-0.07 EPS on August, 14.They anticipate $0.02 EPS change or 22.22 % from last quarter’s $-0.09 EPS. After having $-0.07 EPS previously, CAS Medical Systems, Inc.’s analysts see 0.00 % EPS growth. The stock increased 3.13% or $0.06 during the last trading session, reaching $1.98. About 237,436 shares traded or 49.91% up from the average. CAS Medical Systems, Inc. (NASDAQ:CASM) has risen 67.37% since July 14, 2017 and is uptrending. It has outperformed by 54.80% the S&P500.

CAS Medical Systems, Inc., a non-invasive cerebral oximetry technology company, develops, makes, and markets non-invasive patient monitoring products worldwide. The company has market cap of $54.76 million. The Company's FORE-SIGHT® Absolute Cerebral Oximeter provides non-invasive and continuous measurement of absolute cerebral tissue oxygenation in the brain for patients during critical care. It currently has negative earnings. The firm provides FORE-SIGHT tissue oximeter monitors, sensors, and accessories.

More news for CAS Medical Systems, Inc. (NASDAQ:CASM) were recently published by: Investingnews.com, which released: “Medical Device Update: Q2 2018 in Review” on July 12, 2018. Benzinga.com‘s article titled: “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” and published on June 20, 2018 is yet another important article.

CAS Medical Systems, Inc. (NASDAQ:CASM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: